Status:
COMPLETED
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Lead Sponsor:
Nektar Therapeutics
Conditions:
Locally Recurrent Breast Cancer
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic...
Eligibility Criteria
Inclusion
- Inclusion Criteria (major highlights):
- Patient is an adult female with histologically or cytologically confirmed carcinoma of the breast for whom single-agent cytotoxic chemotherapy is indicated
- Patient can have either measurable or non-measurable disease by RECIST.
- Patient has received prior therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) with an anthracycline, a taxane and capecitabine
- Patient has minimum of 2 and a maximum of 5 prior cytotoxic chemotherapy regimens with the last dose administered within 6 months. A minimum of two chemotherapy regimens had to be for locally recurrent and/or metastatic disease. All therapy received prior to a diagnosis of metastatic disease (eg, neoadjuvant, adjuvant or repeated adjuvant therapy following a second resection) is counted as one regimen.
- Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate hematopoietic, liver and kidney functions.
- Exclusion Criteria (major highlights):
- Patient with chemotherapy within 21 days, radiotherapy within 14 days, biological therapy with 14 days, hormonal therapy within 7 days and investigational therapy within 21 days prior to randomization.
- Patient with any major surgery within 28 days prior to randomization.
- Patient with concurrent use of biologic agents for the treatment of cancer including antibodies or any investigational agent(s).
- Patient with prior treatment for cancer with a camptothecin derivative.
- Patient with chronic or acute GI disorders resulting in diarrhea of any severity grade; patients who are using chronic anti-diarrheal supportive care to control diarrhea in the 28 days prior to randomization.
- Patient received pharmacotherapy for hepatitis B or C, tuberculosis or HIV.
- Patient with known cirrhosis diagnosed with Child-PUGH Class A or higher liver disease.
- Patient with prior malignancy (other than breast cancer) except for non-melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 5 years prior to randomization.
- Patient requiring daily use of oxygen supplementation in the 28 days prior to randomization.
- Patients with significant cardiovascular impairment.
Exclusion
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
852 Patients enrolled
Trial Details
Trial ID
NCT01492101
Start Date
December 1 2011
End Date
June 1 2016
Last Update
June 1 2021
Active Locations (153)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Oncology Associates, PC - NAHOA
Flagstaff, Arizona, United States, 86001
2
Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center
Burbank, California, United States, 91505
3
University of Southern California
Los Angeles, California, United States, 90033
4
PMK Medical Group, Inc., DBA Ventura County Hematology Oncology Specialists
Oxnard, California, United States, 93030